Sensitive drug distribution system and method

Details Sensitive drug distribution system and method Sensitive drug distribution system and method

2002-12-17

2010-02-23

O'Connor, Gerald J. (Department: 3686)

Data processing: financial, business practice, management, or co

Automated electrical financial or business practice or...

Health care management

C705S003000, C600S300000

Reexamination Certificate

active

07668730

ABSTRACT:
A drug distribution system and method utilizes a central pharmacy and database to track all prescriptions for a sensitive drug. Information is kept in the database regarding all physicians allowed to prescribe the sensitive drug, and all patients receiving the drug. Abuses are identified by monitoring data in the database for prescription patterns by physicians and prescriptions obtained by patients. Further verification is made that the physician is eligible to prescribe the drug by consulting a separate database, and optionally whether any actions are taken against the physician. Multiple controls beyond those for normal drugs are imposed on the distribution depending on the sensitivity of the drug.

REFERENCES:
patent: 3556342 (1971-01-01), Guarr
patent: 4847764 (1989-07-01), Halvorson
patent: 4976351 (1990-12-01), Mangini et al.
patent: 5737539 (1998-04-01), Edelson et al.
patent: 5845255 (1998-12-01), Mayaud
patent: 5924074 (1999-07-01), Evans
patent: 6021392 (2000-02-01), Lester et al.
patent: 6045501 (2000-04-01), Elsayed et al.
patent: 6055507 (2000-04-01), Cunningham
patent: 6112182 (2000-08-01), Akers et al.
patent: 6315720 (2001-11-01), Williams et al.
patent: 6347329 (2002-02-01), Evans
patent: 6564121 (2003-05-01), Wallace et al.
patent: 6755784 (2004-06-01), Williams et al.
patent: 6952681 (2005-10-01), McQuade et al.
patent: 7058584 (2006-06-01), Kosinski et al.
patent: 2001/0001144 (2001-05-01), Kapp
patent: 2001/0042050 (2001-11-01), Fletcher et al.
patent: 2001/0047281 (2001-11-01), Keresman, III et al.
patent: 2002/0010661 (2002-01-01), Waddington et al.
patent: 2002/0032581 (2002-03-01), Reitberg
patent: 2002/0032582 (2002-03-01), Feeney, Jr. et al.
patent: 2002/0042725 (2002-04-01), Mayaud
patent: 2002/0042762 (2002-04-01), McQuade et al.
patent: 2002/0052762 (2002-05-01), Kobylevsky et al.
patent: 2002/0161607 (2002-10-01), Subich
patent: 2002/0177232 (2002-11-01), Melker et al.
patent: 2003/0033168 (2003-02-01), Califano et al.
patent: 2003/0046110 (2003-03-01), Gogolak
patent: 2003/0050802 (2003-03-01), Jay et al.
patent: 2003/0110060 (2003-06-01), Clementi
patent: 2003/0127508 (2003-07-01), Jones
patent: 2003/0144876 (2003-07-01), Kosinski et al.
patent: 2003/0160698 (2003-08-01), Andreasson et al.
patent: 2003/0197366 (2003-10-01), Kusterbeck
patent: 2003/0229519 (2003-12-01), Eidex et al.
patent: 2003/0233256 (2003-12-01), Cardenas et al.
patent: 2004/0008123 (2004-01-01), Carrender et al.
patent: 2004/0019567 (2004-01-01), Herceg et al.
patent: 2004/0019794 (2004-01-01), Moradi et al.
patent: 2004/0078237 (2004-04-01), Kaafarani et al.
patent: 2004/0107117 (2004-06-01), Denny
patent: 2004/0117126 (2004-06-01), Fetterman et al.
patent: 2004/0122712 (2004-06-01), Hill, Sr. et al.
patent: 2004/0122713 (2004-06-01), Hill, Sr. et al.
patent: 2004/0162740 (2004-08-01), Ericsson et al.
patent: 2004/0176985 (2004-09-01), Lilly et al.
Ukens, C. “Specialty Pharmacy,” Jun. 5, 2000, Drug Topics, v. 144, p. 40.
“An Interview with Orphan Medical about Xyrem,” http://www.talkaboutsleep.com/sleep-disorders/archives/Narcolepsy—xyrem—interview.htm, Feb. 12, 2001.
NASCSA National Conference, (Nov. 2000), 8 pages.
“Diversion Prevention Through Responsible Distribution”,NADDI Regional Training, (May 2001), 12 pages.
“Diversion Prevention Through Responsible Distribution”,NADDI Regional Training Tennessee, (Jun. 2001), 14 Pages.
“Diversion Prevention Through Responsible Distribution”,NADDI National Conference, (Nov. 2001), 15 pages.
“Peripheral and Central Nervous System Drugs Advisory Committee”,Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research, Holiday Inn, Bethesda, Maryland, (Jun. 6, 2001), 7 pages.
Preliminary Amendment Pursuant to 37 CFR 1.115 filed with United States Patent and Trademark Office on Jun. 17, 2005 in U.S. Appl. No. 11/104,013 (3 pages).
“System for Thalidomide Education and Prescribing Safety (S.T.E.P.S.) Starter Kit”,Celgene Corporation, (2001),103 pgs.
“U.S. Appl. No. 11/097,985, Preliminary Amendment mailed Apr. 1, 2005”, 7 pgs.
“U.S. Appl. No. 11/097,985 Non Final Office Action Mailed Sep. 14, 2009”, 22.
“U.S. Appl. No. 10/731,915, Non Final Office Action Response mailed Feb. 2, 2005”, 17 pgs.
“U.S. Appl. No. 10/979,665, Preliminary Amendment mailed Nov. 2, 2004”, 3 pgs.
“U.S. Appl. No. 11/097,651, Preliminary Amendment mailed Apr. 1, 2005”, 6 pgs.
“U.S. Appl. No. 11/097,651, Non-Final Office Action mailed May 29, 2009”, 21 pgs.
“U.S. Appl. No. 11/097,651, Response filed Sep. 17, 2009 to Non Final Office Action mailed May 29, 2009”, 10 pgs.

Affiliated with

Also associated with

Rating

Sensitive drug distribution system and method does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Sensitive drug distribution system and method, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sensitive drug distribution system and method will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4181006